Market Place
Sourcing Support
Akeso, Summit`s PD-1xVEGF drug meets OS goal for the first time
27 Aug 2025 //
FIERCE PHARMA
Akeso’s Anniko enters crowded US PD-1 market
25 Apr 2025 //
FIERCE PHARMA
Akeso to Host 2024 Financial Results Call on March 31, 2025
28 Mar 2025 //
PR NEWSWIRE
Akeso To Share Strategy At 43rd J.P. Morgan Healthcare Conference
06 Jan 2025 //
PR NEWSWIRE
Akeso To Present At Citi & Evercore 2024 Healthcare Conferences
28 Nov 2024 //
PR NEWSWIRE
Akeso Secures $250M USD For Global Expansion
13 Oct 2024 //
PR NEWSWIRE
Ivonescimab Gets Priority Review For First-Line NSCLC Treatment In China
14 Aug 2024 //
PR NEWSWIRE
Two Ivonescimab Results For NSCLC To Be Presented At WCLC 2024
12 Aug 2024 //
PR NEWSWIRE
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08 Jan 2024 //
PR NEWSWIRE
Akeso invests RMB 850 M to establish Shanghai Global R&D Centre
30 Nov 2023 //
BIOSPECTRUM ASIA
Akeso Launches Construction of Shanghai Global R&D Center
28 Nov 2023 //
PR NEWSWIRE
Akeso`s bispecific notches ph. 3 victory against gastric cancer
08 Nov 2023 //
FIERCE BIOTECH
Akeso Announced 2023 Interim Results: 1st Profit, Growing Sales of PD-1/CTLA-4
29 Aug 2023 //
PR NEWSWIRE
Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA
25 Aug 2023 //
PR NEWSWIRE
Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab
24 Aug 2023 //
PR NEWSWIRE
Specialised signs partnership agreement with Akeso Inc. and CTTQ-Akeso
11 Apr 2023 //
PR NEWSWIRE
Akeso Reported 2022 Annual Results
15 Mar 2023 //
PR NEWSWIRE
China NMPA Approved for First-line Treatment of Metastatic Squamous NSCLC
15 Jan 2023 //
PRESS RELEASE
Summit bets $5B that Akeso’s bispecific will reach cancer peak
07 Dec 2022 //
FIERCEBIOTECH
Akeso concludes subject enrolment in Phase III NSCLC antibody trial
07 Nov 2022 //
CLINICALTRIALSARENA
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific)
30 Oct 2022 //
PRNEWSWIRE
Akeso receives NMPA approval for PhIb/II trial of Ivonescimab & drebuxelimab
18 Oct 2022 //
PHARMABIZ
Akeso`s Cadonilimab included in the 2022 CSCO Guidelines
16 Oct 2022 //
PRNEWSWIRE
Akeso Is Developing Therapies Based on PD-1 BsAbs PD-1/VEGF with CD73
16 Oct 2022 //
PRNEWSWIRE
TIGIT/TGF-? fusion protein of Akeso demonstrated results published at ESMO
13 Sep 2022 //
PRNEWSWIRE
First approval of Cadonilimab published in a peer-reviewed medical journal
26 Aug 2022 //
PRNEWSWIRE
Akeso`s Cadonilimab to Treat Cancer, Approved for Marketing in China
29 Jun 2022 //
PRNEWSWIRE
Akeso announces oral presentation on promising clinical data of Cadonilimab
05 Jun 2022 //
PRNEWSWIRE
Akeso releases promising data of Ivonescimab for advanced NSCLC at ASCO 2022
05 Jun 2022 //
PRNEWSWIRE
Akeso Appoints Steven A. Porcelli, MD, to Scientific Advisor Board
17 May 2022 //
GLOBENEWSWIRE
Akeso Publishes Preclinical Results of AK129 at AACR
14 Apr 2022 //
PRNEWSWIRE
Akeso Publishes Preclinical Results of TIGIT MAb, AK127 at AACR
13 Apr 2022 //
PRNEWSWIRE
Akeso Publishes Preclinical Results of AK131 at AACR
13 Apr 2022 //
PRNEWSWIRE
Akeso Reported 2021 Annual Results
01 Apr 2022 //
PRNEWSWIRE
Akeso Announces IND Approval from China NMPA for Phase II Trial of Cadonilimab
07 Mar 2022 //
PRNEWSWIRE
Akeso`s NGF Monoclonal Antibody Approved To Initiate Clinical Trial In Pain
10 Feb 2022 //
PRNEWSWIRE
Akeso`s Ligufalimab, Ivonescimab Obtained Approval To Initiate A Phase II Trial
31 Jan 2022 //
ASIAONE
Akeso gets approval for Phase 1b/2 trial of Cadonilimab+Ivonescimab in NSCLC
06 Jan 2022 //
PRNEWSWIRE
Akeso Acquires Industrial Medical Group
04 Jan 2022 //
BUSINESSWIRE
AKESO`S CADONILIMAB+CHEMORADIOTHERAPY NABS APPROVAL TO INITIATE PHASE III TRIAL
03 Jan 2022 //
BIOSPACE
Akeso`s Gumokimab Completes Enrollment in Phase II for Ankylosing Spondylitis
27 Dec 2021 //
PRNEWSWIRE
Akeso gets Chinese nod to initiate phase II trial of AK112 monotherapy
03 Nov 2021 //
PHARMABIZ
AK112 to Initiate Phase II Trial for Therapy of Resectable NSCLC
01 Nov 2021 //
PRNEWSWIRE
Akeso is rapidly advancing the clinical study of the PD-1/CTLA-4 Cadonilimab
22 Oct 2021 //
PRNEWSWIRE
NDA for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) by NMPA
23 Sep 2021 //
PRNEWSWIRE
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor
30 Jun 2021 //
PR NEWSWIRE
Akeso`s Penpulimab Monoclonal Antibody Submitted BLA in the United States
24 May 2021 //
PRNEWSWIRE
ANTI-PD-1/CTLA-4 Bi-specific Antibody (AK104) of Akeso Granted FDA Fast TRACK
12 Aug 2020 //
PRNEWSWIRE
Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor a
23 Jun 2020 //
PRNEWSWIRE
